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A role for JNK/SAPK in proliferation, but not apoptosis, of 
IL-3-dependent cells
Anna Smith, Francisco Ramos-Morales, Alan Ashworth and Mary Collins*
Activation of c-Jun N-terminal kinase/stress-activated
protein kinase (JNK/SAPK) has been implicated in the
induction of apoptosis in a variety of systems [1–8].
BAF3 cells are pre-B cells that undergo apoptosis
following IL-3 withdrawal or ceramide treatment [9,10].
JNK/SAPK in BAF3 cells is stimulated by ceramide and
also during cell proliferation in response to IL-3 [11],
but its role in the apoptotic response is not clear. We
have devised a method of selectively inhibiting
JNK/SAPK activity using a dual-specificity
threonine/tyrosine phosphatase, M3/6. Expression of
this phosphatase in BAF3 cells prevented ceramide
stimulation of JNK/SAPK activity but did not affect
apoptosis following IL-3 withdrawal or ceramide
treatment. IL-3-stimulated proliferation of BAF3 cells
expressing the phosphatase was, however, inhibited.
Hence JNK/SAPK activation is likely to be involved in
the proliferative response of these cells but is not
required for apoptosis. Selective ablation by dual-
specificity phosphatases should be a general method
for determining the functions of specific mitogen-
activated kinase pathways.
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Results and discussion
M3/6 is a dual-specificity phosphatase that selectively
inactivates JNK/SAPK, with a lesser effect on p38 (HOG
kinase) and no effect on extracellular signal-regulated
kinase ERK2 [12,13]. BAF cell lines stably transfected
with myc-tagged M3/6 complementary DNA (cDNA) were
generated. The expression level of tagged M3/6 in five
cell clones was determined by Western blot analysis
(Figure 1a). Three clones expressed a detectable level of
tagged M3/6. Expression of M3/6 had no effect on IL-3-
induced ERK2 activation as measured by gel mobility shift
(Figure 1b), supporting previous studies [13]. Stimulation
of p38 phosphorylation by supraphysiological levels of IL-
3 has been reported [11]. However, we observed only a
modest increase in p38 phosphorylation in response to the
level of IL-3 required to stimulate proliferation (Figure 1c)
and M3/6 expression did not affect the level of phosphory-
lated p38 (Figure 1c). Previous studies have suggested
that M3/6 inactivates p38 to some extent, in addition to
inactivating JNK/SAPK [13]. The apparent difference in
substrate specificity observed here might be due to differ-
ences in the subcellular localization of M3/6, which is
nuclear in some cell types but both nuclear and cytosolic
in others, or may be due to overexpression of M3/6 in the
transient transfection assay used previously [13]. In BAF3
cells expressing M3/6, IL-3-induced activation of JNK/
SAPK was inhibited, as measured by a glutathione S-trans-
ferase (GST)–Jun pull-down assay (Figure 1d). Similar
selective inhibition of JNK/SAPK activation was also
observed in clones M3/6-3 and M3/6-5 (data not shown).
An increase in JNK/SAPK upon IL-3 removal from mast
cells has been described [14]; however, little JNK/SAPK
activity was observed two hours after IL-3 removal from
BAF3 cells (Figure 1d).
The death rates of cells expressing various levels of M3/6,
following withdrawal of IL-3, were identical (Figure 2a),
demonstrating that JNK/SAPK activity was not required
for apoptosis upon IL-3 removal. Ceramide has previ-
ously been reported to induce apoptosis by stimulating
JNK/SAPK activity [3,4]. In BAF3 cells, M3/6 also inhib-
ited ceramide-induced JNK/SAPK activity (Figure 2b).
However, M3/6 did not affect induction of apoptosis by
ceramide, measured either as appearance of apoptotic cells
by flow cytometry (Figure 2c), or as loss of viability
(Figure 2d). Induction of apoptosis by ceramide was
slowed in the presence of IL-3; this protective effect was
not inhibited by M3/6 (Figure 2c,d).
Cells overexpressing M3/6 required higher concentrations
of IL-3 for survival (Figure 3a); clone M3/6-1, which
expressed the highest level of tagged M3/6, required a 10-
fold higher concentration of IL-3 to maintain half-maximal
viability compared to control cells. IL-3-stimulated prolif-
eration, measured by [3H]thymidine incorporation, was
also decreased in cells overexpressing M3/6 (Figure 3b).
The reduction in IL-3 stimulation of proliferation corre-
lated with the level of expression of M3/6 (compare
Figure 3b with Figure 1a); the highest expressing clone,
M3/6-1, again required a 10-fold higher concentration of
IL-3 to stimulate half-maximal proliferation compared to
control cells. A low level of JNK/SAPK activity in M3/6-1
cells was stimulated by the levels of IL-3 required to stim-
ulate cell proliferation (compare Figure 3b and Figure 1d).
Because a complete inhibition of JNK/SAPK activation in
cells overexpressing M3/6 was not observed, we cannot
determine whether any cell proliferation would occur in
its absence.
Expression of dominant negative forms of JNK/SAPK, or
of its upstream activators the kinases ASK1 and SEK1, or
of its downstream target c-Jun, blocks apoptosis in
response to γ-irradiation, removal of nerve growth factor,
treatment with tumour necrosis factor (TNF), heat shock,
cisplatin, and ceramide treatment [1–8]. However, cells
from mice lacking SEK1 show normal apoptosis in response
to environmental stress [15], while TNF activates JNK/
SAPK by a signalling pathway that does not result in apop-
tosis [16,17]. JNK/SAPK activity has also previously been
implicated in cell transformation. JNK/SAPK is activated by
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Figure 1
Selective inhibition of JNK/SAPK by M3/6. 
(a) Immunoblot with antibody to the Myc
epitope showing levels of tagged M3/6
expression in five BAF3 cell clones. Expression
levels were quantitated by densitometric
analysis; M3/6-1: 1.90 OD units × mm2; 
M3/6-3: 1.62 OD units × mm2; 
M3/6-5: 1.39 OD units × mm2. BAF3 cells
transfected with empty pBABEpuro (vector)
and M3/6-expressing BAF3 cells (M3/6-1)
were deprived of IL-3 for 2 h and then
stimulated for 15 min with increasing
concentrations of IL-3 followed by analysis of
(b) ERK2 activity by gel mobility shift, (c) p38
activity by immunoblots with antibodies to
phosphorylated p38 and to non-
phosphorylated p38, and (d) JNK/SAPK
activity by GST–Jun pull-down assay and
control immunoblot with antibody to
JNK/SAPK. Equal amounts of protein were
assayed for each lane.
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Figure 2
Lack of inhibition of ceramide-induced
apoptosis by M3/6. (a) Death rate of BAF3
cells expressing M3/6 following IL-3
withdrawal. (b) BAF3 cells transfected with
empty pBABEpuro (vector) and M3/6-
expressing BAF3 cells (M3/6-1), deprived of
IL-3 for 2 h, were stimulated with 7 nM IL-3,
50 µM C6-ceramide or a combination for
15 min, then a GST–Jun pull-down assay of
JNK/SAPK activity was performed. Equal
amounts of protein were assayed for each
lane. (c) Apoptotic cells detected by flow
cytometry after treatment of cells for 4 h with
7 nM IL-3 and C6-ceramide as indicated. 
(d) Cell viability after treatment for 15 h with
7 nM IL-3 and C6-ceramide as indicated.
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the Rac and Cdc42 GTPases, although this activation is not
essential for Rac stimulation of proliferation, or cytoskele-
tal reorganization [18–20]. JNK/SAPK is constitutively
active in T cells transformed by the intracellular parasite
Theileria parva [21] and activation of the JNK/SAPK
pathway has been shown to be required for cell transfor-
mation by both the Bcr-Abl and Tpr-Met oncogenes,
using dominant negative mutants of c-Jun or Grb2 [22,23].
However, the overexpression of dominant negative pro-
teins to block signalling pathways could result in the inhi-
bition of other related pathways. Our system, utilizing a
dual-specificity phosphatase to inhibit JNK/SAPK activity,
is likely to be much more specific. Using this phosphatase,
we show that JNK/SAPK activation is not required for
induction of apoptosis by IL-3 removal or ceramide treat-
ment. Also, our data suggest for the first time that JNK/
SAPK activation is required for stimulation of cell prolifera-
tion by IL-3. Activation of either Ras or ERK2 alone is not
sufficient to stimulate cell proliferation in the absence of
IL-3 [24,25]. JNK/SAPK activation, which requires Ras
activation plus an additional signal [26], is a potential effec-
tor step at which Ras and additional tyrosine kinase-depen-
dent pathways might integrate to stimulate proliferation in
response to cytokines.
Materials and methods
Cell culture and transfection
BAF3 cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% fetal bovine serum and 5% WEHI-3B cell-
conditioned medium as a source of IL-3. M3/6 cDNA, fused to a myc
epitope tag, was cloned into the vector pBABEpuro [27]. Cells were
electroporated with M3/6 plasmid using a Gene Pulser (BioRad) with
capacitance extender at 300 V, 960 µF. Single-cell clones were iso-
lated at limiting dilution in 4 µg ml–1 puromycin.
Analysis of cell proliferation and viability
IL-3 was removed by washing twice in medium lacking IL-3. Recombi-
nant murine IL-3 was purchased from R&D Systems and C6-ceramide
from Calbiochem. Cell viability was determined by counting total and
Trypan Blue-excluding cells on a haemocytometer and cell prolifera-
tion by incubating cells for 4 h with 5 µCi ml–1 [3H]thymidine (20 Ci
mmol–1, Amersham International), isolating labelled DNA with a Dyna-
tech cell harvester and scintillation counting. Apoptotic cells were quanti-
tated by fixing cells in cold 70% ethanol/30% phosphate-buffered
saline (PBS), resuspending cells in PBS and incubating for 30 min at
37°C with 100 µg ml–1 RNase A and 40 µg ml–1 propidium iodide.
The fluorescence of stained cells was analysed using LYSIS II soft-
ware on a FACScan. Apoptotic cells were defined as those with sub-
G1 DNA content.
Analysis of ERK2, JNK/SAPK and p38 activities
Phosphorylated ERK2 was detected by gel mobility shift. Cell lysate
(20 µg) was separated on a 15% sodium dodecyl sulphate (SDS)–
polyacrylamide gel, transferred to nitrocellulose and probed with ERK2
antiserum (no. 122).
Activated p38 was detected using a phospho-p38-specific antibody
(New England Biolabs). Total p38 levels were determined using an
antibody to p38 (New England Biolabs).
JNK/SAPK activity was assayed in a pull-down assay. Cell lysate
(250 µg) was incubated with 5 µg recombinant glutathione S-trans-
ferase (GST)–Jun (amino acids 1–131) fusion protein for 3 h at 4°C.
GST–Jun was then captured on 20 µl glutathione–Sepharose beads
(Pharmacia) by incubation for a further 1 h. The beads were washed
four times with HBIB buffer [20 mM HEPES (pH 8.0), 0.05% Triton
X-100, 50 mM NaCl, 20 mM β-glycerophosphate, 2.5 mM MgCl2,
0.1 mM EDTA, 100 µM Na3VO4] and once with Jun kinase buffer
[20 mM HEPES (pH 8.0), 20 mM β-glycerophosphate, 20 mM MgCl2,
100 µM Na3VO4, 0.5 mM dithiothreitol (DTT)]. The beads were then
incubated with 30 µl Jun kinase buffer including 20 µM ATP and
66 µCi [γ-32P]ATP at 30°C for 30 min. The reaction was terminated
by washing the beads with 1 ml ice-cold HBIB buffer. The beads
were resuspended in 30 µl SDS sample buffer [80 mM Tris (pH 6.8),
2% SDS, 10% glycerol, 100 µM DTT, 0.02% bromophenol blue],
heated at 100°C for 5 min and analysed on a 10% SDS–polyacry-
lamide gel. The gel was dried and subjected to autoradiography.
JNK/SAPK levels were determined using a JNK/SAPK-specific anti-
body (New England Biolabs).
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Figure 3
Inhibition of IL-3-stimulated survival and
proliferation by M3/6. (a) Survival of BAF3
cells expressing M3/6 after 24 h in the
presence of various concentrations of IL-3. 
(b) Proliferation of BAF3 cells expressing
M3/6 during a 4 h labelling period after 20 h
in the presence of various concentrations of
IL-3.
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